Comparing the current results to its competitors, Durect reported Revenue decrease in the 2 quarter 2025 year on year by -79.41 %, faster than the overall decrease of Durect's competitors by -2.7 %, recorded in the same quarter.
Durect's Comment on Competition and Industry Peers
The biopharmaceutical industry faces challenges related to patent protection and intellectual property rights. Patents owned or licensed may not fully prevent competitors from independently developing similar technologies. Patent applications can be challenged or invalidated, and the extended development and regulatory approval process may reduce the effective patent life. Orphan drug exclusivity can prevent approval of competing products for seven years under specific conditions. Regulatory agencies such as the FDA impose significant requirements on product development, manufacturing, and marketing. Orphan drug status in the European Union offers comparable but distinct benefits and requirements. After approval, products continue to be subject to ongoing FDA regulation.
Mira Pharmaceuticals Inc's business model is focused on the development and sale of pharmaceutical products, with a particular emphasis on research and innovation in the healthcare industry.
Milestone Pharmaceuticals Inc. is a pharmaceutical company that focuses on developing and commercializing innovative therapies for cardiovascular diseases. Their business model revolves around identifying unmet medical needs in the cardiovascular space and leveraging their expertise in drug development to create novel treatments. By conducting rigorous research, clinical trials, and collaborations, Milestone Pharmaceuticals aims to bring effective and safe medications to market, positively impacting patients' lives.
Mallinckrodt Plc's business model revolves around acquiring and developing branded pharmaceutical products, as well as manufacturing and distributing generic and specialty pharmaceuticals. They aim to address unmet medical needs and improve patient lives through their diverse portfolio of drugs.
Merus N V is a biotechnology company that operates using a differentiated and competitive business model. Their approach involves strategically targeting and developing bispecific antibodies to treat various types of cancer, leveraging their proprietary technologies and expertise in the field. By focusing on innovative research, efficient drug discovery, and partnerships, they aim to improve patient outcomes and drive growth in the oncology market.
Sources:
Durect Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Durect Corp versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
